5. (Amended) The method of claim [4] 1 wherein the endogenous antigen is the acetylcholine receptor, insulin, growth hormone, factor VIII or factor IX.

7. (Amended) The method of claim [6] 2 wherein the exogenous antigen is a fungal antigen.

17. (Five times amended) A method to tolerize a human to an endogenous antigen associated with aberrant, pathogenic or undesirable antibody production in the human, comprising: administering to the respiratory tract of the human at least one epitope peptide, having a universal immunodominant epitope sequence, wherein the administration is effective to tolerize $CD4^+$ cells which are associated with antibody production to the endogenous antigen, in humans having divergent HLA haplotypes [to the endogenous antigen] and wherein the peptide comprises less than the sequence of the antigen.

42. (Amended) The method of claim [2] 1 wherein the peptide includes residues 150-169, 181-200 or 360-378 of the *Torpedo californica* acetylcholine receptor alpha subunit or a portion of those residues.

Please add the following claim:

44. (New) The method of claim 1 or 17 wherein the antigen is factor VIII.

Remarks

Reconsideration and withdrawal of the rejections of the claims, in view of the amendments and remarks presented herein, is respectfully requested. Claims 2, 5, 7, 17, and 42 are amended, claims 4, 6, and 8-12 are canceled, and claim 44 is added; as a result, claims 1-3, 5, 7, 13, 16-18, 31, 34-39, and 41-44 are pending in this application.

Support for amended claim 2 is found in originally-filed claims 8-9.

Amended claims 5 and 7 are supported by originally-filed claim 5 and 7, respectively.

Amended claim 42 is supported by Example 1 in the specification.

Support for new claim 44 is found in originally-filed claim 12.